From another forum:
Telmisartan really seems to be an outlier among ARBs with unique properties. In this paper just published in the American Journal of Hypertension: "BP control was similar in both groups; however, telmisartan users exhibited significantly lower visit-to-visit BP variability" (BPV). (Three-Year Cardiovascular Outcomes of Telmisartan in Patients with Hypertension: An Electronic Health Record-Based Cohort Study Get access Arrow 2).
The adjusted 3-year MACE rate was similar between telmisartan users (4.6%) and other ARB users (4.7%, log-rank p = 0.75), with comparable safety profiles, but as "BPV had a stronger association with dementia and cognitive impairment than mean BP levels" 1 I would bet that telmisartan users will have lower rates of dementia and all-cause mortality years later (and that's what most studies tend to find).
Other interesting properties of telmisartan vs other ARBs:
- "By leveraging the National Health Insurance Research Database, a Taiwanese study [78] found that the dementia risk was lower in telmisartan users compared with other ARB users (hazard
ratio, 0.72; 95% CI, 0.53 to 0.97; p = 0.030). The authors attributed this to the greater effect of
telmisartan on increasing PPAR-y expression." (Angiotensin Receptor Blockers and Cognition: a
Scoping Review 1 2023)
- "Among seven ARBs (azilsartan, candesartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan), telmisartan was the most effective ARB for the increase of adiponectin secretion" (Telmisartan is the most effective ARB to increase adiponectin via PPARa in adipocytes 2022)
- "Telmisartan can better improve IR compared with other ARBs." (Telmisartan Improves Insulin
Resistance: A Meta-Analysis 1 2018)
Also, for Covid: "Death by day 30 was reduced in the telmisartan-treated group (control 22.54%, 16/71; telmisartan 4.29%, 3/70 participants; p = 0.0023). Composite ICU, mechanical ventilation or death was reduced by telmisartan treatment at days 15 and 30. No adverse events were reported." (Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial, 2021).